Browse by Day Archive

CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis

10/04/2026 4:17pm
Australia's CSL said on Monday it had entered into an agreement ​with Swiss drugmaker Alentis Therapeutics to co-develop and co-promote a treatment for rare kidney and liver diseases, in a deal worth up ‌to $1.6 billion, excluding development funding.